Amgen 2009 Annual Report Download - page 44

Download and view the complete annual report

Please find page 44 of the 2009 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

The following table is a selection of certain of our product candidates by phase of development in our ther-
apeutic areas of focus as of February 5, 2010. Each target indication for product candidates in phase 3 is listed
separately. For products in phase 1 and 2, the most advanced indication is shown. Additional product candidate
(pipeline) information can be found on our website at http://www.amgen.com. (This website address is not intended
to function as a hyperlink, and the information contained on our website is not intended to be a part of this filing.)
Molecule Disease/Condition Therapeutic Area
Phase 3 Programs
Sensipar®(cinacalcet) Cardiovascular disease in patients with secondary hyperparathyroidism
and chronic kidney disease undergoing maintenance dialysis
Nephrology
Aranesp®(darbepoetin alfa) Anemia in heart failure Nephrology
Prolia™ (denosumab) Postmenopausal osteoporosis Bone
Denosumab Male osteoporosis Bone
Denosumab Cancer-related bone damage (skeletal-related events) from advanced
malignancies in breast cancer, prostate cancer and solid tumors
including multiple myeloma
Hematology/Oncology
Denosumab Prevention of bone metastases in prostate cancer Hematology/Oncology
Denosumab Prevention of bone metastases in breast cancer Hematology/Oncology
Prolia™(denosumab) Bone loss induced by hormone ablation therapy in breast cancer or
prostate cancer
Hematology/Oncology
Motesanib First-line non-small cell lung cancer Hematology/Oncology
Vectibix®(panitumumab) First- and second-line colorectal cancer Hematology/Oncology
Vectibix®(panitumumab) Metastatic and/or recurrent head and neck cancer Hematology/Oncology
Phase 2 Programs
AMG 102 Various cancer types Hematology/Oncology
AMG 108 Rheumatoid arthritis Inflammation
AMG 222 Type 2 diabetes General Medicine
AMG 223 Hyperphosphatemia Nephrology
AMG 386 Various cancer types Hematology/Oncology
AMG 479 Various cancer types Hematology/Oncology
AMG 785 Bone-related conditions, including postmenopausal osteoporosis and
fracture healing
Bone
AMG 827 Inflammatory diseases Inflammation
AMG 853 Asthma Inflammation
Conatumumab (AMG 655) Various cancer types Hematology/Oncology
Denosumab Rheumatoid arthritis Inflammation
Dulanermin (rhApo2L/TRAIL) Various cancer types Hematology/Oncology
Motesanib First-line breast cancer Hematology/Oncology
Omecamtiv mecarbil (AMG 423) Heart failure General Medicine
Vectibix®(panitumumab) Locally advanced head and neck cancer Hematology/Oncology
Nplate®(romiplostim) Chemotherapy-induced thrombocytopenia in non-small cell lung cancer
and lymphoma
Hematology/Oncology
Nplate®(romiplostim) Myelodysplastic syndromes Hematology/Oncology
Phase 1 Programs
AMG 145 Hypercholesterolemia General Medicine
AMG 151 Type 2 diabetes General Medicine
AMG 157 Asthma Inflammation
AMG 167 Bone-related conditions Bone
AMG 191 Inflammatory diseases Inflammation
AMG 208 Various cancer types Hematology/Oncology
AMG 221 Type 2 diabetes General Medicine
AMG 557 Systemic lupus erythematosus Inflammation
AMG 745 Muscle-wasting disorders General Medicine
AMG 747 Neuroscience General Medicine
AMG 761 Asthma Inflammation
AMG 811 Systemic lupus erythematosus Inflammation
AMG 820 Various cancer types Hematology/Oncology
AMG 888 Various cancer types Hematology/Oncology
AMG 900 Various cancer types Hematology/Oncology
Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.
Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease
or condition under study.
Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or con-
dition under study.
32